Video

Ari R. Cohen, MD, FAAP: Epinephrine Recommended for Pediatric Anaphylaxis

Author(s):

Cohen believes the emergency injection is not only cost-effective but the ideal treatment method for protecting vulnerable pediatric groups with allergies.

Though anaphylaxis has been thoroughly discussed in the field of allergy and pediatric research, the recommendations for treatment may vary, especially when considering pediatric populations.

In an interview with HCPLive, Ari R. Cohen, MD, FAAP, Chief of Pediatric Emergency Medicine, Massachusetts General Hospital, spoke of the efficacy and safety of emergency epinephrine injections, which he believed to be the first choice in treating pediatric patients in most cases.

Cohen spoke on this subject in his presentation, “Anaphylaxis Update: Be Prepared!”, a session which occurred at the American Academy of Pediatrics (AAP) 2021 Virtual Conference this weekend.

Several parent-reported studies were incorporated into Cohen’s session, many of which detailed the myriad of different symptoms younger patients experience with anaphylaxis.

Though some symptoms such as rashes and respiratory distress are noticeable by caregivers and clinicians, others such as motility of the intestines or vomiting might not immediately be considered symptoms relating to anaphylaxis.

Regardless, Cohen noted that several treatment methods such as the use of steroids have been commonly accepted in caregiver and clinical groups. However, he added that steroids, unlike epinephrine, do not provide immediate medical relief in the case anaphylaxis.

Epinephrine, he said, provides not only immediate relief for pediatric patients experiencing anaphylaxis, but is also a cost-effective and widely available treatment method.

In emergency rooms, for instance, epinephrine can be administered by nurses via standard vials and injections.

Cohen hoped that the future of anaphylaxis treatment in pediatric populations would entail the de-stigmatization of epinephrine in both caregiver and clinical communities, citing “little downside” to its use.

“So I think that my general principle is that think about epinephrine as the treatment for anaphylaxis; if you do nothing else from this session, that's the thing you should take home,” Cphen said, “Most people in pediatrics and that take care of kids understand that, but you should not delay giving epinephrine to give anything else.”

To hear more from Dr. Cohen on his AAP session on anaphylaxis, watch the video above.

Related Videos
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
© 2024 MJH Life Sciences

All rights reserved.